Endogenous sex steroid hormones and risk of liver cancer among US men: Results from the Liver Cancer Pooling Project.
Androgen
Liver cancer
Male
Oestrogen
Sex steroid hormone
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
31
10
2022
revised:
28
02
2023
accepted:
03
03
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Incidence rates of liver cancer in most populations are two to three times higher among men than women. The higher rates among men have led to the suggestion that androgens are related to increased risk whereas oestrogens are related to decreased risk. This hypothesis was investigated in the present study via a nested case-control analysis of pre-diagnostic sex steroid hormone levels among men in five US cohorts. Concentrations of sex steroid hormones and sex hormone-binding globulin were quantitated using gas chromatography-mass spectrometry and a competitive electrochemiluminescence immunoassay, respectively. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs for associations between hormones and liver cancer among 275 men who subsequently developed liver cancer and 768 comparison men. Higher concentrations of total testosterone (OR per one-unit increase in log Higher concentrations of both androgens (testosterone, dihydrotestosterone) and their aromatised oestrogenic metabolites (oestrone, oestradiol) were observed among men who subsequently developed liver cancer compared with men who did not. As DHEA is an adrenal precursor of both androgens and oestrogens, these results may suggest that a lower capacity to convert DHEA to androgens, and their subsequent conversion to oestrogens, confers a lower risk of liver cancer, whereas a greater capacity to convert DHEA confers a greater risk. This study does not fully support the current hormone hypothesis as both androgen and oestrogen levels were associated with increased risk of liver cancer among men. The study also found that higher DHEA levels were associated with lower risk, thus suggesting the hypothesis that greater capacity to convert DHEA could be associated with increased liver cancer risk among men.
Sections du résumé
Background & Aims
UNASSIGNED
Incidence rates of liver cancer in most populations are two to three times higher among men than women. The higher rates among men have led to the suggestion that androgens are related to increased risk whereas oestrogens are related to decreased risk. This hypothesis was investigated in the present study via a nested case-control analysis of pre-diagnostic sex steroid hormone levels among men in five US cohorts.
Methods
UNASSIGNED
Concentrations of sex steroid hormones and sex hormone-binding globulin were quantitated using gas chromatography-mass spectrometry and a competitive electrochemiluminescence immunoassay, respectively. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs for associations between hormones and liver cancer among 275 men who subsequently developed liver cancer and 768 comparison men.
Results
UNASSIGNED
Higher concentrations of total testosterone (OR per one-unit increase in log
Conclusions
UNASSIGNED
Higher concentrations of both androgens (testosterone, dihydrotestosterone) and their aromatised oestrogenic metabolites (oestrone, oestradiol) were observed among men who subsequently developed liver cancer compared with men who did not. As DHEA is an adrenal precursor of both androgens and oestrogens, these results may suggest that a lower capacity to convert DHEA to androgens, and their subsequent conversion to oestrogens, confers a lower risk of liver cancer, whereas a greater capacity to convert DHEA confers a greater risk.
Impact and implications
UNASSIGNED
This study does not fully support the current hormone hypothesis as both androgen and oestrogen levels were associated with increased risk of liver cancer among men. The study also found that higher DHEA levels were associated with lower risk, thus suggesting the hypothesis that greater capacity to convert DHEA could be associated with increased liver cancer risk among men.
Identifiants
pubmed: 37425211
doi: 10.1016/j.jhepr.2023.100742
pii: S2589-5559(23)00073-3
pmc: PMC10326694
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100742Déclaration de conflit d'intérêts
The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Oncology. 2010 Jul;78 Suppl 1:172-9
pubmed: 20616601
Prev Med. 1973 Jun;2(2):197-206
pubmed: 4723635
J Gastroenterol Hepatol. 2020 Dec;35(12):2210-2219
pubmed: 32343449
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 1991 Aug 24;338(8765):464-8
pubmed: 1678444
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Cancer. 2002 May 1;94(9):2490-501
pubmed: 12015775
Endocrinology. 2019 Oct 1;160(10):2395-2400
pubmed: 31199478
Mol Cell Endocrinol. 2018 Apr 15;465:4-26
pubmed: 28865807
J Steroid Biochem. 1982 Jun;16(6):801-10
pubmed: 7202083
J Gastroenterol Hepatol. 2015 Aug;30(8):1237-45
pubmed: 25708186
Endocr Relat Cancer. 2014 May 06;21(3):R165-82
pubmed: 24424503
J Natl Cancer Inst. 2000 Dec 20;92(24):2023-8
pubmed: 11121465
N Engl J Med. 1990 Oct 11;323(15):1026-32
pubmed: 2215561
Eur J Gastroenterol Hepatol. 1995 Feb;7(2):145-50
pubmed: 7712307
Drugs. 2014 Jul;74(11):1195-207
pubmed: 25022952
Hepatology. 2020 Aug;72(2):535-547
pubmed: 31808181
Mol Cell Endocrinol. 2002 Jul 31;193(1-2):59-63
pubmed: 12161002
J Gastroenterol Hepatol. 2016 Jun;31(6):1210-9
pubmed: 26574916
J Clin Pharmacol. 1999 Apr;39(4):327-48
pubmed: 10197292
Am J Clin Nutr. 2001 Jan;73(1):61-7
pubmed: 11124751
Coll Antropol. ;40(3):211-8
pubmed: 29139641
Cancer Res. 1993 Feb 15;53(4):790-4
pubmed: 8381328
Control Clin Trials. 2000 Dec;21(6 Suppl):349S-355S
pubmed: 11189687
Prog Brain Res. 2010;181:177-92
pubmed: 20478438
Cancer Res. 2000 Sep 15;60(18):5106-10
pubmed: 11016636
Oncology. 2001;60(4):355-60
pubmed: 11408804
Cancer. 1993 Jan 15;71(2 Suppl):589-93
pubmed: 8420681
N Engl J Med. 1989 Jul 20;321(3):129-35
pubmed: 2664509
J Natl Cancer Inst. 2001 Nov 7;93(21):1644-51
pubmed: 11698569
J Hepatol. 1997 Jan;26(1):96-102
pubmed: 9148029
Liver. 2000 Jun;20(3):228-33
pubmed: 10902973
J Pathol. 2012 Oct;228(2):216-29
pubmed: 22374713
Int J Cancer. 2021 Aug 1;149(3):573-584
pubmed: 33720423
Int J Cancer. 2021 Feb 1;148(3):609-625
pubmed: 32734650
Int J Cancer. 1995 Nov 15;63(4):491-3
pubmed: 7591255
Int J Cancer. 2014 Jan 1;134(1):164-73
pubmed: 23801371
Cancer Prev Res (Phila). 2011 May;4(5):735-43
pubmed: 21430073
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012